Objective: To compare the safety, efficacy and management of insulin lispro (LP) with regular human insulin (RH) in young diabetic children treated with continuous subcutaneous insulin infusion (CSII). Study Design: 27 very young diabetic children (age 4.6 ± 2.2 years) treated with CSII participated in an open-label, randomized cross-over multicenter study comparing 2 periods of 16 weeks of CSII with LP or RH. Results: Mean daily basal rate was significantly higher during the LP period (p = 0.04). No differences were seen in changes in HbA1c levels, number of hypoglycemic events, cutaneous infections and catheter occlusions. There was no significant difference between the two treatments for preprandial and postprandial glucose values, although prandial glucose excursions tended to be lower with LP (significant at dinner, p = 0.01). Mean blood glucose levels were significantly higher at 0.00 and 3.00 a.m. during LP therapy (p < 0.05). No episode of ketoacidosis occurred during LP treatment. More parents indicated that LP made their own and the child’s daily life easier (p = 0.02) and preferred LP (p = 0.01). Conclusions: LP in CSII therapy in children is safe, as effective as RH, improved postprandial excursions, met the needs of young children in their daily life well, and gained their parents’ satisfaction and preference. However, a shorter duration of LP resulted in hyperglycemia during the first part of the night, which must be compensated for by increasing nocturnal basal rates during this time.

Keywords:
Type-1 diabetes, Diabetic children, Continuous subcutaneous insulin infusion, Metabolic control, Quality of life
1.
Tubiana-Rufi N, Czernichow P: Special problems and management of the child less than 5 years of age; in Sperling MA (ed): Type 1 Diabetes: Etiology and Treatment. Totowa, Humana Press, 2003, pp 279–292.
2.
Porter PA, Keating B, Byrne G, Jones TW: Incidence and predictive criteria of nocturnal hypoglycemia in young children with insulin-dependent diabetes mellitus. J Pediatr 1997;130:366–372.
3.
Beregszaszi M, Tubiana-Rufi N, Benali K, Noel M, Bloch J, Czernichow P: Nocturnal hypoglycemia in children and adolescents with insulin-dependent diabetes mellitus: Prevalence and risk factors. J Pediatr 1997;131:27–33.
4.
Mortensen HB, Hougaard P: Comparison of metabolic control in a cross-sectional study of 2,873 children and adolescents with IDDM from 18 countries. The Hvidore Study Group on Childhood Diabetes. Diabetes Care 1997;20:714–720.
5.
Komulainen J, Kulmala P, Savola K , Lounamaa R, Ilonen J, Reijonen H, et al: Clinical, autoimmune, and genetic characteristics of very young children with type 1 diabetes. Childhood Diabetes in Finland (DiMe) Study Group. Diabetes Care 1999;22:1950–1955.
6.
Chaussain J-L, Geaorges P, Calzada L, Job J-C: Glycemic response to 24-hour fast in normal children. III. Influence of age. J Pediatr 1977;91:711–714.
7.
Matyka K, Crowne EC, Havel PJ, Macdonald IA, Matthews DM, Dunger DB: Counterregulation during spontaneous nocturnal hypoglycemia in prepubertal children with type 1 diabetes. Diabetes Care 1999;22:1144–1150.
8.
Barkai L, Vamosi I, Lukacs K: Prospective assessment of severe hypoglycemia in diabetic children and adolescents with impaired and normal awareness of hypoglycemia. Diabetologia 1998;41:898–890.
9.
Silva SR, Clark L, Goodman SN, Plotnick LP: Can caretakers of children with IDDM accurately measures small insulin doses and dose changes? Diabetes Care 1999;19:56–59.
10.
Bougnères PF, Landier F, Lemmel C, Mensire A, Chaussain JL: Insulin pump therapy in young children with type 1 diabetes. J Pediatr 1984;105:212–217.
11.
Joseph MG, Ginies JL, Chomienne F, Limal JM: Traitement du diabète insulinodépendant par pompe à insuline chez l’enfant d’âge inférieur à 7 ans. Arch Pédiatr 1992;49:505–510.
12.
Tubiana-Rufi N, de Lonlay P, Bloch J, Czernichow P: Remission of severe hypoglycemia incidents in young diabetic children treated with subcutaneous insulin infusion. Arch Pediatr 1996;3:969–976.
13.
Litton J, Rice A, Friedman N, Oden J, Lee MM, Freemark M: Insulin pump therapy in toddlers and preschool children with type 1 diabetes mellitus. J Pediatr 2002;141:490–495.
14.
Ahern JAH, Boland EA, Doane R, Ahern JJ, Rose P, Vincent M, et al: Insulin pump therapy in pediatrics: A therapeutic alternative to safely lower HbA1c level across all age groups. Pediatr Diabetes 2002;3:10–15.
15.
Zinman B, Tildesley H, Chiasson JL, Tsui E, Strack T: Insulin Lispro in CSII. Results of a double-blind crossover study. Diabetes 1997;46:440–443.
16.
Melki V, Renard E, Lassman-Vague V, Bovin S, Guerci B, Hanaire-Broutin H, et al: Improvement of HbA1c and blood glucose stability in IDDM patients treated with insulin lispro analog in external pumps. Diabetes Care 1998;21:977–982.
17.
Renner R, Pfützner A, Trautmann M, Harzer O, Sauter K, Landgraf R on behalf of the German Humalog-CSII Study Group: Use of insulin lispro in continuous subcutaneous insulin infusion treatment. Results of a multicenter trial. Diabetes Care 1999;22:784–788.
18.
Holcombe J, Zalani S, Arora V, Headlee S, Gill A: Insulin lispro (LP) results in less nocturnal hypoglycemia compared with regular human insulin in adolescents with type 1 diabetes (abstract). Diabetes 1997;46(suppl 1):A0402.
19.
Holcombe J, Brunelle R, Zalani S, Deeb LC: Comparative study of insulin lispro and regular insulin in prepubertal children with type 1 diabetes (abstract). Diabetes 1998;47(suppl 1): A96.
20.
Kaufman FR, Halvorson M, Kim C, Pitukcheewanont P: Use of insulin pump therapy at nighttime only for children 7–10 years of age with type 1 diabetes. Diabetes Care 2000;23:579–582.
21.
Maniatis AK, Klingensmith GJ, Slover RH, Mowry CJ, Chase HP: Continuous subcutaneous insulin infusion therapy for children and adolescents: An option for routine diabetes care. Pediatrics 2001;107:351–356.
22.
Conrad SC, McGrath MT, Gitelman SE: Transition from multiple daily injections to continuous subcutaneous insulin infusion in type 1 diabetes mellitus. J Pediatr 2002;140:235–240.
23.
Colquitt J, Royle P, Waugh N: Are analogue insulins better than soluble in continuous subcutaneous insulin infusion? Results of a meta-analysis. Diabetic Med 2003;20:863–866.
24.
Guerci B, Meyer L, Salle A, Charrie A, Dousset B, Ziegler O, et al: Comparison of metabolic deterioration between insulin analog and regular insulin after a 5-hour interruption of a of continuous subcutaneous insulin infusion in type 1 diabetic patients. J Clin Endocrinol Metab 1999;84:2673–2678.
25.
Attia N, Jones TW, Holcombe J, Tamborlane WV: Comparison of human regular and lispro insulins after interruption of continuous subcutaneous insulin infusion and in the treatment of acutely decompensated IDDM. Diabetes Care 1998;21:817–821.
26.
Karjaleinen J, Salmela P, Ilonen J, Surcel HM, Knip M: A comparison of childhood and adult type 1 diabetes mellitus. N Engl J Med 1989;320:881–886.
27.
Ludvigsson J, Hanas R: Continuous subcutaneous glucose monitoring improved metabolic control in pediatric patients with type 1 diabetes: A controlled crossover study. Pediatrics 2003;111:933–938.
© 2004 S. Karger AG, Basel
2004
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.